Opens in a new tab

10x Genomics v Vizgen (CFI, ORD_49363/2024, 24 October 2024)

Date24 October 2024
CourtCFI
DivisionHamburg (DE) Local Division
Type of actionApplication RoP262A
Registry referenceApp_49295/2024 · ORD_49363/2024
Parties10x Genomics, Inc., President and Fellows of Harvard College v. Vizgen, Inc.

Official decision (PDF) · UPC registry entry

Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.

Contact the firm

Dhenne Avocats · 10 October 2026

Our analysis

Summary

By order of 24 October 2024 (UPC_CFI_22/2023, ACT_460565/2023, ORD_49363/2024), the judge-rapporteur of the Hamburg Local Division (S. Klepsch), in the infringement action on EP 4 108 782 brought by 10x Genomics and President and Fellows of Harvard College against Vizgen, restricted access to a licence agreement filed as exhibit BP 34 to the parties’ outside counsel and their staff. The Registry published it under two entries.

Question

May access to confidential information be denied to every natural person of the opposing party, although Rule 262A.6 RoP in principle requires access for at least one person per party?

Decision

Trade secret status need not be established with certainty: it is enough that it is more likely than not, and Vizgen did not dispute that the agreement was confidential. Rule 262A.6 RoP requires access for at least one natural person per party, unless the parties agree to restrict access to outside counsel. Here the parties had agreed by emails in June 2024 to a regime comparable to the protective order in the parallel action before the District of Delaware. The equal treatment argument based on the wider access regime for the licence filed by Vizgen does not undo that agreement. The information may not be used outside the proceedings, even after they end, and any breach may lead to a penalty payment. The order is not appealable and leave to appeal is not granted of the court’s own motion (Rule 220 RoP).

Key points for practice

Provisions applied

Agreement on a Unified Patent Court
Art. 58
Rules of Procedure
Rules 220, 262A, 331.1, 334 and 335
Other provisions
Directive (EU) 2016/943, Arts. 2 and 9
Case law cited
Plant-e v Arkyne, The Hague Local Division, 4 March 2024, 10x Genomics v Vizgen, Hamburg Local Division, 15 August 2024

Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.


Decisions in the same proceedings

Going further

Lexicon: Confidentiality club.

Source and translations

Official source
Unified Patent Court registry link recorded in the record
Original language
not recorded
Translation available
no translation recorded the firm’s French record is a summary, not a translation
Date checked
not recorded
Only the official text is authoritative. A machine translation is never presented as official, republishing a third-party document requires a verified basis in rights, and a link to the source is preferred.

Follow this case

Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.

Proceedings

No case number recorded in this record.

Parties

Exact name as it appears in the record, group affiliation only where sourced and dated.

Decisions in the same proceedings and documented appeals

No other decision in the corpus bears the same case number, and no appeal is documented in the corpus to date.

What the record states

Nature of the act
Application RoP262A
Outcome (Dhenne Avocats summary)
Le contrat de licence produit par les demanderesses est déclaré confidentiel et son accès réservé aux avocats des parties et à leurs secrétariats, les parties étant convenues d'un tel régime.
Appeal
No appeal documented in the corpus, this does not mean that no appeal was lodged.
Instance
First-instance decision, whether it has become final is not recorded.

Patents mentioned

Related decisions cited in the analyses

Scope: Dhenne Avocats corpus. Registry-based links are marked “official number”; links derived from the analyses are marked as such. An erroneous link can be withdrawn without deleting any record.

Patents and standards

PublicationRole in the disputeFamilyStandard and declarationPoolSources
EP 4 108 782
Compositions and methods for analyte detection
recorded proprietor: Harvard University
Mentioned in the analysis (role not qualified)
Also mentioned in 18 other decision(s): NanoString Technologies v 10x Genomics (CoA, 11 March 2024) · 10x Genomics v NanoString (CFI, 19 September 2023) · 10x Genomics v Bruker Spatial Biology (CFI, 11 April 2025) · 10x Genomics v Vizgen (CoA, 11 March 2025) · 10x Genomics v Vizgen (CoA, 5 March 2025) · 10x Genomics v Vizgen (CFI, 20 December 2024) · NanoString Technologies v 10x Genomics (CoA, 10 December 2024) · 10x Genomics v Vizgen (CFI, 1 November 2024)
not recordednot recordednot recordedEspacenet · European Patent Register
existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically)
mentioned in: Dhenne Avocats analysis
The statuses “asserted in litigation”, “declared essential”, “listed by a pool” and “essentiality examined by a court” are distinct and may coexist. Validity, infringement and technical essentiality are different questions. Scope: patents cited in the decisions of the Dhenne Avocats corpus, with no essentiality score or prediction.

Receive an alert

Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.

Follow

Weekly summary, on Fridays.